NANX / Solesence, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Solesence, Inc.
US ˙ OTCPK ˙ US6300791018
HINDI NA ACTIVE ANG SIMBONG ITO

Mga Batayang Estadistika
CIK 883107
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Solesence, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
September 4, 2025 EX-10.3

EMPLOYMENT AGREEMENT

Solésence, Inc. 8-K Exhibit 10.3 EMPLOYMENT AGREEMENT This Amended Employment Agreement dated and effective as of September 3, 2025 (this “Agreement”), between SOLESENCE, INC., a Delaware corporation (with its successors and assigns, referred to as the “Company”), and Laura Riffner, (referred to as Employee”). Preliminary Statement The Company desires to employ Employee, and Employee wishes to be

September 4, 2025 EX-10.1

EMPLOYMENT AGREEMENT

Solésence, Inc. 8-K Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement dated and effective as of September 3, 2025 (this “Agreement”), is made between Solésence, Inc. f/k/a Nanophase Technologies Corporation, a Delaware corporation (with its successors and assigns, referred to as the “Company”), and Kevin Cureton (“Mr. Cureton”). Preliminary Statement Mr. Cureton has been continuously emp

September 4, 2025 EX-99.1

Solésence Announces Key Leadership Appointments to Drive Future Innovation and Growth Strategic transformation of Solésence continues with Kevin Cureton promoted to President and Chief Executive Officer; Laura Riffner named Chief Financial Officer; J

Solésence, Inc. 8-K Exhibit 99.1 Solésence Announces Key Leadership Appointments to Drive Future Innovation and Growth Strategic transformation of Solésence continues with Kevin Cureton promoted to President and Chief Executive Officer; Laura Riffner named Chief Financial Officer; Jess Jankowski to serve as Board Advisor Romeoville, Ill., September 3, 2025 – Solésence, Inc. (Nasdaq: SLSN), a leade

September 4, 2025 EX-10.2

TRANSITION EMPLOYMENT AGREEMENT

Solésence, Inc. 8-K Exhibit 10.2 TRANSITION EMPLOYMENT AGREEMENT This Transition Employment Agreement dated and effective as of September 3, 2025 (this “Agreement”), is made between Solésence, Inc. f/k/a Nanophase Technologies Corporation, a Delaware corporation (with its successors and assigns, referred to as the “Company”), and Jess Jankowski (“Mr. Jankowski”). Preliminary Statement Mr. Jankowsk

September 4, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 SOLÉSENCE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 SOLÉSENCE, INC. (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Employer jurisdiction of File Num

August 29, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 SOLÉSENCE, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 SOLÉSENCE, INC. (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Employer jurisdiction of File Numbe

August 14, 2025 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Solésence, Inc. (

July 31, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 SOLESENCE, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File Numb

July 31, 2025 EX-99.1

Solésence Reports Second Quarter 2025 Financial Results Strong commercial execution drove revenue growth of 56% to $20.4 million

EXHIBIT 99.1 Solésence Reports Second Quarter 2025 Financial Results Strong commercial execution drove revenue growth of 56% to $20.4 million ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) - Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the second quarter ended June 30, 2025

July 30, 2025 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

June 9, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 SOLÉSENCE, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 SOLÉSENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-42589 36-3687863 (State or other (Commission (IRS Employer jurisdiction of File Number

June 9, 2025 EX-3.1

Certificate of Correction, filed June 3, 2025, to the Company’s Certificate of Amendment to the Company’s Certificate of Incorporation.

SOLESENCE, INC 8-K Exhibit 3.1 Delaware Page 1 The First State            I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF CORRECTION OF “SOLESENCE, INC.”, FILED IN THIS OFFICE ON THE THIRD DAY OF JUNE, A.D. 2025, AT 4:35 O`CLOCK P.M. 2820214 8100 Authentication: 203861879 SR# 20252963635 Date

June 2, 2025 EX-10.1

Term Loan Agreement Amendment, dated May 27, 2025.

Solesence, Inc. 8-K Exhibit 10.1 THIRD AMENDMENT TO BUSINESS LOAN AGREEMENT This Third Amendment is dated as of May 27, 2025 and is by and between SOLÉSENCE, INC. (f/k/a NANOPHASE TECHNOLOGIES CORPORATION), a Delaware corporation (“Borrower”) in favor of STRANDLER, LLC, a South Dakota limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022

June 2, 2025 8-K

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-42589 36-3687863 (State or other (Commission (IRS Employer jurisdiction of File Number

June 2, 2025 EX-10.2

A/R Loan Agreement Amendment, dated May 27, 2025.

Solesence, Inc. 8-K Exhibit 10.2 THIRD AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN AGREEMENT This Third Amendment is dated as of May 27, 2025 and is by and between SOLÉSENCE, INC., a Delaware corporation (F/K/A NANOPHASE TECHNOLOGIES CORPORATION) (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Amended and Restated Business Loan A

June 2, 2025 EX-10.3

Revolving Loan Agreement Amendment, dated May 27, 2025.

Solesence, Inc. 8-K Exhibit 10.3 THIRD AMENDMENT TO BUSINESS LOAN AGREEMENT This Third Amendment is dated as of May 27, 2025 and is by and between SOLÉSENCE, INC., a Delaware corporation (F/K/A NANOPHASE TECHNOLOGIES CORPORATION) (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 ( as

June 2, 2025 EX-99.1

Solésence Expands Debt Facilities to Fuel Growth Initiatives

Solesence, Inc. 8-K Exhibit 99.1 Solésence Expands Debt Facilities to Fuel Growth Initiatives Romeoville, Ill., June 2, 2025 – Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it entered into amendments on May 27, 2025 to its existing loan agreements, providing increased borrowing capacity to sup

May 13, 2025 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Solesence, Inc.

May 7, 2025 EX-99.2

Solésence First Quarter 2025 Conference Call Script

EdgarFiling Exhibit 99.2 Solésence First Quarter 2025 Conference Call Script Operator Introduction Good day. Thank you for standing by. Welcome to the Solésence first quarter 2025 conference call. [Operator Instructions] Today's call is being recorded. During this call, management will make statements that include forward-looking statements within the meaning of the federal securities laws, which

May 7, 2025 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File Number

May 7, 2025 EX-99.1

Solésence Reports Record First Quarter 2025 Financial Results First quarter revenue increased 48% to a record $14.6 million

Exhibit 99.1 Solésence Reports Record First Quarter 2025 Financial Results First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) - Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025. Rece

April 7, 2025 EX-99.1

Solésence Announces Uplisting to Nasdaq Trading set to begin Tuesday, April 8 under new ticker “SLSN”

EXHIBIT 99.1 Solésence Announces Uplisting to Nasdaq Trading set to begin Tuesday, April 8 under new ticker “SLSN” ROMEOVILLE, Ill., April 07, 2025 (GLOBE NEWSWIRE) - Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has received approval from the Listing Qualifications Department of Nasdaq to t

April 7, 2025 8-A12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Solesence, Inc. (Exact name of registrant as specified in its charter) Delaware 36-3687863 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 1319 Marquette Drive

April 7, 2025 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File Numb

March 31, 2025 EX-21

SUBSIDIARY OF SOLESENCE INC. (as of December 31, 2024)

Solesence, Inc. 10-K Exhibit 21.1 SUBSIDIARY OF SOLESENCE INC. (as of December 31, 2024) Name Jurisdiction of Formation Solésence, LLC Delaware

March 31, 2025 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 SOLESENCE, INC. (Exact nam

March 31, 2025 EX-19

Explanation of the Law

Solesence, Inc. 10-K Exhibit 19 Solésence, Inc. 1319 Marquette Drive Romeoville, Illinois 60446 TO: All Directors, Advisory Board Members, Officers and Employees of Solésence FROM: Insider Trading Compliance Officer, Jess Jankowski DATE: March 7, 2025 RE: Amended Policy on Insider Trading In the course of employment or other relationship with Solésence, Inc. (“Solésence” or the “Company”), directo

March 26, 2025 EX-99.1

Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million

EXHIBIT 99.1 Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) - Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, to

March 26, 2025 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File Num

March 12, 2025 8-K

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Employer jurisdiction of File Number

March 12, 2025 EX-3.1

Certificate of Amendment to the Company’s Certificate of Incorporation, filed March 10, 2025.

Exhibit 3.1

January 16, 2025 EX-3.1

Nanophase Technologies Corporation 8-K

Nanophase Technologies Corporation 8-K Exhibit 3.1

January 16, 2025 8-K

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) (Com

December 26, 2024 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation)

December 23, 2024 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

November 12, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2024 ☐ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Te

October 30, 2024 EX-99.1

Nanophase Reports Record Third Quarter Revenue and Profit

EXHIBIT 99.1 Nanophase Reports Record Third Quarter Revenue and Profit —Nanophase Reports Q3 Revenue Record at $16.9 Million with Solésence Revenue up 171% YOY  —Record $3 Million in Q3 Profit ROMEOVILLE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science c

October 30, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation)

August 9, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Technol

August 6, 2024 EX-99.1

Nanophase Reports Record Second Quarter Revenue and Profit

EXHIBIT 99.1 Nanophase Reports Record Second Quarter Revenue and Profit —$13 Million in Q2 Revenue, with Solésence Revenue up 44% YOY —$1.7 Million in Profit for the First Half of 2024 alongside Record Q2 Profit —Record Third Win in a Row at Cosmoprof and Cosmopack North America ROMEOVILLE, Ill., Aug. 06, 2024 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral

August 6, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (

May 31, 2024 DEF 14A

SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.

May 29, 2024 CORRESP

Nanophase Technologies Corporation 1319 Marquette Drive · Romeoville, IL 60446 · Phone: 630-771-6700/Fax: 630-771-0825

May 24, 2024 Securities and Exchange Commission Division of Corporate Finance 100F Street, NE Washington, DC 20549 Attn: Mr.

May 21, 2024 PRE 14A

SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.

May 13, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Techno

April 23, 2024 EX-99.1

Nanophase Reports Record First Quarter Results

EXHIBIT 99.1 Nanophase Reports Record First Quarter Results — Delivered $9.9 Million in Q1 Revenue — $0.9 Million in Profit — BASF Litigation Resolved ROMEOVILLE, Ill., April 23, 2024 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect

April 23, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (

April 11, 2024 EX-99.2

SETTLEMENT AGREEMENT AND GENERAL RELEASE

Exhibit 99.2 SETTLEMENT AGREEMENT AND GENERAL RELEASE This Settlement Agreement and General Release (“Agreement”) is made and entered into by and between BASF Corp. (“BASF”) and Nanophase Technologies Corp. (“Nanophase”) (as defined herein) (each a “Party,” and collectively, the “Parties”). WHEREAS, BASF filed the Lawsuit against Nanophase arising from the Parties’ Zinc Oxide Supply Agreement, ame

April 11, 2024 8-K

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 (April 10, 2024) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of i

April 11, 2024 EX-99.1

Nanophase Announces Successful Litigation Settlement

EXHIBIT 99.1 Nanophase Announces Successful Litigation Settlement ROMEOVILLE, Ill., April 11, 2024 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — announced today

April 11, 2024 EX-10.1

Amendment No. 5, effective as of April 10, 2024, to Zinc Oxide Supply Agreement, dated as of September 16, 1999, between Nanophase Technologies Corporation and BASF Corporation.*

EXHIBIT 10.1 AMENDMENT NO. 5 TO ZINC OXIDE SUPPLY AGREEMENT THIS AMENDMENT NO. 5 (“Amendment No. 5”) to the Zinc Oxide Supply Agreement is entered into as of April 10, 2024, (“Amendment No. 5 Effective Date”) and is made by and between BASF CORPORATION, a Delaware corporation (“BASF” or “Purchaser”) and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Nanophase”). Nanophase and BASF ar

March 28, 2024 EX-21.1

SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2023)

NANOPHASE TECHNOLOGIES CORPORATION 10-K EXHIBIT 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2023) Name Jurisdiction of Formation Solésence, LLC Delaware

March 28, 2024 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR

March 21, 2024 EX-99.1

Nanophase Reports Fourth Quarter and Year End 2023 Results, New Financing Package

EXHIBIT 99.1 Nanophase Reports Fourth Quarter and Year End 2023 Results, New Financing Package — Delivered $37.3 million in full year revenue — Closed on $6 million financing — Won 2024 Cosmetics and Toiletries Allē Award Finished Formula Prestige Category ROMEOVILLE, Ill., March 20, 2024 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientific

March 21, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (

March 5, 2024 EX-99.1

NANOPHASE ANNOUNCES $6M FINANCING

Nanophase Technologies Corporation 8-K Exhibit 99.1 Nanophase Technologies Corporation 1319 Marquette Drive Romeoville, IL 60446 NANOPHASE ANNOUNCES $6M FINANCING Romeoville, Ill., March 5, 2024 – Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin

March 5, 2024 EX-10.1

Securities Purchase Agreement, dated March 1, 2024.

Nanophase Technologies Corporation 8-K Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (“Agreement”) dated as of March 1, 2024 by and between STRANDLER, LLC, a South Dakota limited liability company (“Purchaser”), and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (the “Company”). W I T N E S S E T H: WHEREAS, the Company, and its subsidiary, SOLÉSENCE, LLC, a

March 5, 2024 EX-10.2

Term Loan Agreement Amendment, dated March 1, 2024.

Nanophase Technologies Corporation 8-K Exhibit 10.2 SECOND AMENDMENT TO BUSINESS LOAN AGREEMENT This Second Amendment is dated as of March 1, 2024 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of STRANDLER, LLC, a South Dakota limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 (a

March 5, 2024 EX-10.4

Revolving Loan Agreement Amendment, dated March 1, 2024.

Nanophase Technologies Corporation 8-K Exhibit 10.4 SECOND AMENDMENT TO BUSINESS LOAN AGREEMENT This Second Amendment is dated as of March 1, 2024 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 (as am

March 5, 2024 EX-3.1

Certificate of Designations, filed March 4, 2024.

Nanophase Technologies Corporation 8-K Exhibit 3.1 CERTIFICATE OF DESIGNATIONS of SERIES X PREFERRED STOCK of NANOPHASE TECHNOLOGIES CORPORATION (Pursuant to Section 151 of the Delaware General Corporation Law) NANOPHASE TECHNOLOGIES CORPORATION, a corporation organized and existing under the General Corporation Law of the State of Delaware (hereinafter called the "Company"), hereby certifies that

March 5, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 NANOPHASE TECHNOLOG

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) (Com

March 5, 2024 EX-10.3

A&R Loan Agreement Amendment, dated March 1, 2024

Nanophase Technologies Corporation 8-K Exhibit 10.3 SECOND AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN AGREEMENT This Second Amendment is dated as of March 1, 2024 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Amended and Restated Business Loan Agr

December 20, 2023 CORRESP

Nanophase Technologies Corporation 1319 Marquette Drive Romeoville, Illinois 60446 (630) 771-6708 December 19, 2023

Nanophase Technologies Corporation 1319 Marquette Drive Romeoville, Illinois 60446 (630) 771-6708 December 19, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.

December 19, 2023 EX-10.69

RIGHTS OFFERING BACKSTOP AGREEMENT

Nanophase Technologies Corporation S-1/A Exhibit 10.69 RIGHTS OFFERING BACKSTOP AGREEMENT This Rights Offering Backstop Agreement (this “Agreement”) is dated as of November 13, 2023 and is by and among NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (the “Company”), BRADFORD T. WHITMORE, an individual (“Whitmore”), GRACE INVESTMENTS, LP, a Delaware limited partnership (“Grace”), and STR

December 19, 2023 EX-99.6

NANOPHASE TECHNOLOGIES CORPORATION SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF SUBSCRIPTION RIGHTS NOMINEE HOLDER CERTIFICATION

Nanophase Technologies Corporation S-1/A Exhibit 99.6 NANOPHASE TECHNOLOGIES CORPORATION SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF SUBSCRIPTION RIGHTS NOMINEE HOLDER CERTIFICATION The undersigned, a bank, broker, trustee, depository or other nominee holder of subscription rights (the “Subscription Rights”) to purchase shares of common stock, par value $0.01 per share (“Common Stock”), of Na

December 19, 2023 S-1/A

As filed with the Securities and Exchange Commission on December 19, 2023

As filed with the Securities and Exchange Commission on December 19, 2023 Registration No.

December 19, 2023 EX-4.11

THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS (THE “PROSPECTUS”) WHICH FORMS A PART OF THE REGISTRATION STATEMENT ORIGINALLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 21, 2023, AS AMENDE

Nanophase Technologies Corporation S-1/A Exhibit 4.11 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS (THE “PROSPECTUS”) WHICH FORMS A PART OF THE REGISTRATION STATEMENT ORIGINALLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 21, 2023, AS AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PRO

December 19, 2023 EX-99.1

FORM OF INSTRUCTIONS AS TO USE OF NANOPHASE TECHNOLOGIES CORPORATION SUBSCRIPTION RIGHTS CERTIFICATES CONSULT THE SUBSCRIPTION AND INFORMATION AGENT, YOUR BANK OR BROKER AS TO ANY QUESTIONS

Nanophase Technologies Corporation S-1/A Exhibit 99.1 FORM OF INSTRUCTIONS AS TO USE OF NANOPHASE TECHNOLOGIES CORPORATION SUBSCRIPTION RIGHTS CERTIFICATES CONSULT THE SUBSCRIPTION AND INFORMATION AGENT, YOUR BANK OR BROKER AS TO ANY QUESTIONS The following instructions relate to a rights offering by Nanophase Technologies Corporation, a Delaware corporation (“we,” “us,” “our,” or the “Company”),

December 19, 2023 EX-99.3

FORM OF LETTER TO NOMINEE HOLDERS NANOPHASE TECHNOLOGIES CORPORATION Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders of Nanophase Technologies Corporation

Nanophase Technologies Corporation S-1/A Exhibit 99.3 FORM OF LETTER TO NOMINEE HOLDERS NANOPHASE TECHNOLOGIES CORPORATION Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders of Nanophase Technologies Corporation December [●], 2023 To Securities Dealers, Commercial Banks, Trust Companies and Other Nominees: This letter is being

December 19, 2023 EX-99.4

FORM OF LETTER TO CLIENTS OF NOMINEE HOLDERS NANOPHASE TECHNOLOGIES CORPORATION Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders of Nanophase Technologies Corporation

Nanophase Technologies Corporation S-1/A Exhibit 99.4 FORM OF LETTER TO CLIENTS OF NOMINEE HOLDERS NANOPHASE TECHNOLOGIES CORPORATION Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders of Nanophase Technologies Corporation December [●], 2023 To Our Clients: Enclosed for your consideration are a prospectus (the “Prospectus”) wh

December 19, 2023 EX-99.2

FORM OF LETTER TO STOCKHOLDERS WHO ARE RECORD HOLDERS NANOPHASE TECHNOLOGIES CORPORATION Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders of Nanophase Technologies Corporation

Nanophase Technologies Corporation S-1/A Exhibit 99.2 FORM OF LETTER TO STOCKHOLDERS WHO ARE RECORD HOLDERS NANOPHASE TECHNOLOGIES CORPORATION Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders of Nanophase Technologies Corporation December [●], 2023 Dear Stockholder: Enclosed are materials relating to a rights offering by Nan

December 19, 2023 EX-99.5

NANOPHASE TECHNOLOGIES CORPORATION BENEFICIAL OWNER ELECTION

Nanophase Technologies Corporation S-1/A Exhibit 99.5 NANOPHASE TECHNOLOGIES CORPORATION BENEFICIAL OWNER ELECTION I (We), the beneficial owner(s) of shares of common stock, par value $0.01 per share (the “Common Stock”), of Nanophase Technologies Corporation (the “Company”), acknowledge receipt of your letter, the prospectus (the “Prospectus”) which forms a part of the Registration Statement on F

November 21, 2023 EX-FILING FEES

Calculation of Filing Fees Table Form S-1 (Form Type) Nanophase Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Nanophase Technologies Corporation S-1 Exhibit 107.1 Calculation of Filing Fees Table Form S-1 (Form Type) Nanophase Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule or Carry Forward Rule Amount Registered(3) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Of

November 21, 2023 S-1

As filed with the Securities and Exchange Commission on November 21, 2023

As filed with the Securities and Exchange Commission on November 21, 2023 Registration No.

November 14, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2023 or ☐ TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Te

November 14, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation

November 14, 2023 EX-10.3

Exhibit 10.3

Nanophase Technologies Corporation 10-Q Exhibit 10.3 FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT This First Amendment is dated as of November 13, 2023 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 ( a

November 14, 2023 EX-10.1

Exhibit 10.1

Nanophase Technologies Corporation 10-Q Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN AGREEMENT This First Amendment is dated as of November 13, 2023 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Amended and Restated Business Loan

November 14, 2023 EX-99.1

Nanophase Reports Third Quarter Results, New Financing Package

EXHIBIT 99.1 Nanophase Reports Third Quarter Results, New Financing Package  — Closed on $3.2 Million Financing — Delivered $29.3 Million in nine-month revenue     — Won 2023 BeautyMatter NEXT Award — Named as finalist for 22nd annual Chicago Innovation Awards and 2024 Cosmetics & Toiletries Allē Awards ROMEOVILLE, Ill., Nov. 13, 2023 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: N

November 14, 2023 EX-10.5

Exhibit 10.5

Nanophase Technologies Corporation 10-Q Exhibit 10.5 PROMISSORY NOTE (Bridge Note) Principal Amount: $2,000,000.00 Date of Note: November 13, 2023 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), hereby promises to pay to STRANDLER, LLC, a South Dakota limited liability company (“Lender”), or order, in lawful money of the United States of America, the princi

November 14, 2023 EX-10.2

Exhibit 10.2

Nanophase Technologies Corporation 10-Q Exhibit 10.2 REPLACEMENT PROMISSORY NOTE (Revolving Note) Principal Amount: $5,200,000.00 Date of Note: November 13, 2023 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (“Lender”), or order, in lawful money of the United States of America,

November 14, 2023 EX-10.4

Exhibit 10.4

Nanophase Technologies Corporation 10-Q Exhibit 10.4 FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT This First Amendment is dated as of November 13, 2023 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of STRANDLER, LLC, a South Dakota limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022

November 6, 2023 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

August 10, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Technol

August 2, 2023 EX-99.1

Nanophase Reports Record Second Quarter Revenue

EXHIBIT 99.1 Nanophase Reports Record Second Quarter Revenue — Delivered $11.9 Million in Q2 revenue     — Product revenue up 10% in Q2 and 12% YOY — Profitable Quarter — Won Cosmopack Formulation Award at Cosmoprof North America ROMEOVILLE, Ill., Aug. 02, 2023 (GLOBE NEWSWIRE) -   Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care so

August 2, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (

July 21, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 (July 19, 2023) NAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 (July 19, 2023) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of I

July 21, 2023 EX-99.1

Mark E. Miller Joins Nanophase Board of Directors

EXHIBIT 99.1 Mark E. Miller Joins Nanophase Board of Directors ROMEOVILLE, Ill., July 20, 2023 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — is pleased to annou

May 12, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Techno

May 11, 2023 EX-99.1

Nanophase Reports Record First Quarter Revenue for 2023

EXHIBIT 99.1 Nanophase Reports Record First Quarter Revenue for 2023 — Delivered over $9 Million in Q1 revenue — Progressive bottom line improvement through Q1 ROMEOVILLE, Ill., May 11, 2023 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that

May 11, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Co

May 4, 2023 EX-10.1

Promissory Note, dated May 1, 2023, made by Nanophase Technologies Corporation and payable to the order of Beachcorp, LLC to evidence borrowings in a principal amount of up to $1,750,000

Nanophase Technologies Corporation 8-K Exhibit 10.1 PROMISSORY NOTE (Non-Revolving Note - TI) Principal Amount: $1,750,000.00 Date of Note: May 1, 2023 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (“Lender”), or order, in lawful money of the United States of America, the princ

May 4, 2023 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 (May 4, 2023) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Employ

March 29, 2023 EX-99.1

Nanophase Reports Third Consecutive Year of Record Revenue for 2022

EXHIBIT 99.1 Nanophase Reports Third Consecutive Year of Record Revenue for 2022 — Another record year with 27% YOY growth — Delivered $37 Million in full year revenue — In Beauty Science markets, Solésence revenue is up 27% YOY while Active Pharmaceutical Ingredients (API) sales are up 44% ROMEOVILLE, Ill., March 29, 2023 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a lead

March 29, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 NANOPHASE TECHNOLO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (

March 29, 2023 EX-21.1

SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2022)

Nanophase Technologies Corporation 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2022) Name Jurisdiction of Formation Solésence, LLC Delaware

March 29, 2023 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR

March 29, 2023 EX-10.22

3RD AMENDMENT to the Supply Agreement effective as of March 3, 2006 Roche Diagnostics GmbH Sandhofer Strasse 116 68305 Mannheim Nanophase Technologies Corporation 1319 Marquette Drive Romeoville, IL 60446 - “SUPPLIER” -

Nanophase Technologies Corporation 10-K Exhibit 10.22 Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for conf

December 2, 2022 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

November 14, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2022 ☐ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Te

November 8, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation)

November 8, 2022 EX-99.1

Nanophase Reports Strong Revenue for Third Quarter as Growth Continues

EXHIBIT 99.1 Nanophase Reports Strong Revenue for Third Quarter as Growth Continues ? Delivered $9.7 million in Q3 revenue???? ? In Beauty Science markets, Sol?sence revenue is up 39% YOY? ? In Personal Care Ingredients markets, Nanophase revenue is up 61% YOY? ROMEOVILLE, Ill., Nov. 08, 2022 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scient

September 8, 2022 8-K

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 (August 31, 2022) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction

September 8, 2022 EX-99.1

Nanophase Files Complaint for Declaratory Judgment

Nanophase Technologies Corp. 8-K Exhibit 99.1 FOR IMMEDIATE RELEASE? ? ? Nanophase Files Complaint for Declaratory Judgment Romeoville, Ill., Sept. 7, 2022 ? Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories ? with innovations that protect skin from environmental aggressors and aid

August 17, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2022 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation)

August 17, 2022 EX-99.1

Nanophase Reports Record Revenue for Second Quarter as Growth Continues

EXHIBIT 99.1 Nanophase Reports Record Revenue for Second Quarter as Growth Continues ? Delivered a record $11.2 million in Q2 revenue ? In Beauty Science markets, Sol?sence revenue is up 44% YOY while Active Pharmaceutical Ingredients (API) sales are up 79%? ROMEOVILLE, Ill., Aug. 17, 2022 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifi

August 16, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Technol

August 16, 2022 NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

NT 10-Q 1 nanx-nt10q063022.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-22333 CUSIP NUMBER: 630079101 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition R

May 16, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Techno

May 11, 2022 EX-99.1

Nanophase Reports Record Revenue for First Quarter as it Sets Stage for Strong Year

EXHIBIT 99.1 Nanophase Reports Record Revenue for First Quarter as it Sets Stage for Strong Year ? Delivered a record $8.2 million in Q1 revenue ? In Beauty Science markets, Sol?sence revenue is up 29% YOY while Active Pharmaceutical Ingredients (API) sales are up 70%? ? Added key team members to support growth ROMEOVILLE, Ill., May 11, 2022 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (O

May 11, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Co

March 31, 2022 EX-99.1

Set Up For Strong Growth, Nanophase Reports Second Consecutive Year of Record Financial Results for 2021 as Solésence Continues to Lead and Personal Care Ingredients Category Thrives

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Set Up For Strong Growth, Nanophase Reports Second Consecutive Year of Record Financial Results for 2021 as Solésence Continues to Lead and Personal Care Ingredients Category Thrives — Another record year with 70% YOY growth — Delivered $29 Million in full year revenue — In Beauty Science markets, Solésence revenue is up 170% YOY while Active Pharmac

March 31, 2022 EX-21.1

SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2021)

NANOPHASE TECHNOLOGIES CORPORATION 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2021) Name Jurisdiction of Formation Sol?sence, LLC Delaware

March 31, 2022 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR

March 31, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (

February 2, 2022 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 (January 28, 2022) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction

February 2, 2022 EX-10.6

PROMISSORY NOTE (Revolving Note - Inventory)

Nanophase Technologies Corporation 8-K Exhibit 10.6 PROMISSORY NOTE (Revolving Note - Inventory) Principal Amount: $4,000,000.00 Date of Note: January 28, 2022 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (?Lender?), or order, in lawful money of the United States of America, t

February 2, 2022 EX-10.1

BUSINESS LOAN AGREEMENT

Nanophase Technologies Corporation 8-K Exhibit 10.1 BUSINESS LOAN AGREEMENT THIS BUSINESS LOAN AGREEMENT dated as of January 28, 2022 by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), and BEACHCORP, LLC, a Delaware limited liability company (?Lender?). PREAMBLE WHEREAS, Borrower desires to enter into certain secured financial transactions with Lender for the f

February 2, 2022 EX-10.2

BUSINESS LOAN AGREEMENT

Nanophase Technologies Corporation 8-K Exhibit 10.2 BUSINESS LOAN AGREEMENT THIS BUSINESS LOAN AGREEMENT dated as of January 28, 2022 by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), and STRANDLER, LLC, a South Dakota limited liability company (?Lender?). PREAMBLE WHEREAS, Borrower desires to enter into certain secured financial transactions with Lender for t

February 2, 2022 EX-10.5

PROMISSORY NOTE (Term Note)

Nanophase Technologies Corporation 8-K Exhibit 10.5 PROMISSORY NOTE (Term Note) Principal Amount: $1,000,000.00 Date of Note: January 28, 2022 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), hereby promises to pay to STRANDLER, LLC, a South Dakota limited liability company (?Lender?), or order, in lawful money of the United States of America, the principal

February 2, 2022 EX-10.3

AMENDED AND RESTATED BUSINESS LOAN AGREEMENT

Nanophase Technologies Corporation 8-K Exhibit 10.3 AMENDED AND RESTATED BUSINESS LOAN AGREEMENT THIS AMENDED AND RESTATED BUSINESS LOAN AGREEMENT dated as of January 28, 2022 by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), and BEACHCORP, LLC, a Delaware limited liability company (?Lender?). The Agreement amends and restates, in its entirety, that certain Bu

February 2, 2022 EX-10.4

REPLACEMENT PROMISSORY NOTE (Revolving Note - AR)

Nanophase Technologies Corporation 8-K Exhibit 10.4 REPLACEMENT PROMISSORY NOTE (Revolving Note - AR) Principal Amount: $8,000,000.00 Date of Note: January 28, 2022 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (?Lender?), or order, in lawful money of the United States of Ameri

January 14, 2022 SC 13G/A

NANX / Nanophase Technologies Corporation / Conley John Howard Jr Passive Investment

SC 13G/A 1 2021nanx.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Nanophase Technologies Corp (Name of Issuer) Common Stock (Title of Class of Securities) 630079101 (CUSIP Number) (Date of Event which Requires Filing of this Statement) December 31, 2021 Check the appropriate box to designate the

December 9, 2021 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 (December 6, 2021) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (

December 9, 2021 EX-10.1

STANDARD FORM INDUSTRIAL BUILDING LEASE

Nanophase Technologies Corporation 8-K Exhibit 10.1 CERTAIN INFORMATION, MARKED IN THIS EXHIBIT WITH BRACKETS, HAS BEEN EXCLUDED FROM THIS EXHIBIT IN RELIANCE ON REGULATION S-K, ITEM 601(B)(10)(IV) BECAUSE SUCH INFORMATION IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. STANDARD FORM INDUSTRIAL BUILDING LEASE 1. BASIC TERMS: This Section contains

November 23, 2021 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

November 12, 2021 PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

November 4, 2021 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2021 ☐ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Te

November 3, 2021 EX-99.1

Nanophase Technologies Reports Record Financial Results for Third Quarter Ended September 30, 2021

EXHIBIT 99.1 Nanophase Technologies Reports Record Financial Results for Third Quarter Ended September 30, 2021 Announces Another Record Quarter with 80% YOY Growth Delivered $22 Million in Nine-Month Revenue Sol?sence Nine-Month 2021 Revenue Exceeded Full Year 2020 Revenue by More Than 98% ROMEOVILLE, Ill., Nov. 03, 2021 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leade

November 3, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation)

August 17, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (C

August 17, 2021 EX-99.1

Nanophase Reports Record Second Quarter Financial Results as Solésence Beauty Science Growth Continues Announces 69% YOY Growth and $14M in Six-Month Revenue

EXHIBIT 99.1 Nanophase Reports Record Second Quarter Financial Results as Sol?sence Beauty Science Growth Continues Announces 69% YOY Growth and $14M in Six-Month Revenue ROMEOVILLE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across various beauty and life science categories ? w

August 16, 2021 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technologi

August 16, 2021 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2021 ☐ TRANSITION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 N

August 16, 2021 8-K

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 (August 10, 2021) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of

June 14, 2021 EX-10.1

EXCLUSIVE SUPPLY AGREEMENT

Nanophase Technologies Corporation 8-K Exhibit 10.1 CERTAIN INFORMATION, MARKED IN THIS EXHIBIT WITH BRACKETS, HAS BEEN EXCLUDED FROM THIS EXHIBIT IN RELIANCE ON REGULATION S-K, ITEM 601(B)(10)(IV) BECAUSE SUCH INFORMATION IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. EXCLUSIVE SUPPLY AGREEMENT THIS EXCLUSIVE SUPPLY AGREEMENT (?Agreement?), made

June 14, 2021 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 (June 8, 2021) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Emp

May 17, 2021 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technolog

April 27, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 27, 2021 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commis

April 27, 2021 EX-99.1

Nanophase Reports Record First Quarter Financial Results as Solésence Beauty Science Leads Growth Announces 75+% YOY Growth and $7M in Quarterly Revenue

EXHIBIT 99.1 Nanophase Reports Record First Quarter Financial Results as Sol?sence Beauty Science Leads Growth Announces 75+% YOY Growth and $7M in Quarterly Revenue ROMEOVILLE, Ill., April 27, 2021 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically driven health care solutions across various beauty and life science categories ? with

April 21, 2021 EX-10.1

FOURTH AMENDMENT TO BUSINESS LOAN AGREEMENT

NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 FOURTH AMENDMENT TO BUSINESS LOAN AGREEMENT This Fourth Amendment is dated as of April 21, 2021 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?) in favor of BEACHCORP, LLC, a Delaware limited liability company (?Lender?) and amends that certain Business Loan Agreement dated as of November 19, 2018 ( as

April 21, 2021 8-K

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 (April 21, 2021) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS

April 20, 2021 S-8

-

As filed with the Securities and Exchange Commission on April 19, 2021 Registration No.

March 26, 2021 10-K

Annual Report - ANNUAL REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR

March 26, 2021 EX-21.1

SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2020)

NANOPHASE TECHNOLOGIES CORPORATION 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2020) Name Jurisdiction of Formation Sol?sence, LLC Delaware

March 11, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 11, 2021 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commis

March 11, 2021 EX-99.1

Nanophase Reports Record 2020 Financial Results as Solésence Beauty Science and Life Science Materials Lead Growth Announces 35+% Overall Growth and $1M Profit

EXHIBIT 99.1 Nanophase Reports Record 2020 Financial Results as Solésence Beauty Science and Life Science Materials Lead Growth Announces 35+% Overall Growth and $1M Profit ROMEOVILLE, Ill., March 11, 2021 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care innovations across various beauty and life science categorie

February 1, 2021 SC 13G/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Nanophase Technologies Corp (Name of Issuer) Common Stock (Title of Class of Securities) 630079101 (CUSI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Nanophase Technologies Corp (Name of Issuer) Common Stock (Title of Class of Securities) 630079101 (CUSIP Number) (Date of Event which Requires Filing of this Statement) December 31, 2020 Check the appropriate box to designate the rule pursuant to which

December 23, 2020 EX-10.1

Third Amendment, dated December 23, 2020, to Business Loan Agreement between Nanophase Technologies Corporation and Beachcorp, LLC

NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 THIRD AMENDMENT TO BUSINESS LOAN AGREEMENT This Third Amendment is dated as of December 23, 2020 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of November 19, 2018 ( a

December 23, 2020 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2020 (December 23, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission

November 16, 2020 10-Q

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Techn

November 13, 2020 DEF 14A

- DEFINITIVE PROXY STATEMENT

nanx-def14a120920 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

November 4, 2020 8-K/A

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 (October 28, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or

November 3, 2020 EX-99.1

Nanophase Reports Record Third Quarter 2020 Financial Results as Solésence Expands Beauty Footprint Announces 20+% Growth and Record Profitability

EXHIBIT 99.1 Nanophase Reports Record Third Quarter 2020 Financial Results as Solésence Expands Beauty Footprint Announces 20+% Growth and Record Profitability ROMEOVILLE, Ill., Nov. 03, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care innovations across various beauty and life science categories, protecting

November 3, 2020 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 3, 2020 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Comm

October 30, 2020 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 30, 2020 (October 28, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of I

October 30, 2020 EX-99.1

Laura M. Beres Joins Nanophase Board of Directors as Solésence Expands Beauty Footprint

EXHIBIT 99.1 Laura M. Beres Joins Nanophase Board of Directors as Solésence Expands Beauty Footprint ROMEOVILLE, Ill., Oct. 29, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care innovations across beauty and life science categories, is pleased to announce the appointment of Laura M. Beres to its Board of Direc

September 22, 2020 EX-10.1

Second Amendment, dated September 16, 2020, to Business Loan Agreement between Nanophase Technologies Corporation and Beachcorp, LLC

NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 SECOND AMENDMENT TO BUSINESS LOAN AGREEMENT This Second Amendment is dated as of September 8, 2020 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation ("Borrower") in favor of BEACHCORP, LLC, a Delaware limited liability company ("Lender") and amends that certain Business Loan Agreement dated as of November 19, 2018 (

September 22, 2020 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 (September 16, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commissi

September 2, 2020 EX-10.1

AMENDMENT #1 JOINT DEVELOPMENT & SUPPLY AGREEMENT

NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 AMENDMENT #1 JOINT DEVELOPMENT & SUPPLY AGREEMENT This amendment #1 to the Amended and Restated Joint Development & Supply Agreement ("Agreement') is made this 25th day of August 2020 ("Effective Date") between COLORESCIENCE Inc., a company existing and organized under the laws of Delaware, ("COLORESCIENCE') with its principal place of business a

September 2, 2020 8-K

Financial Statements and Exhibits, Entry into a Material Definitive Agreement - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2020 (August 25, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (

August 12, 2020 10-Q

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technologi

August 6, 2020 EX-99.1

Nanophase Reports Record Second Quarter 2020 Financial Results Announces 32% Growth for Quarter, 20% Year-Over-Year, Doubling of Formulated Product Sales and YTD Profitability

EXHIBIT 99.1 Nanophase Reports Record Second Quarter 2020 Financial Results Announces 32% Growth for Quarter, 20% Year-Over-Year, Doubling of Formulated Product Sales and YTD Profitability ROMEOVILLE, Ill., Aug. 06, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environm

August 6, 2020 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 6, 2020 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commis

May 13, 2020 EX-10.1

Exhibit 10.1

Nanophase Technologies Corporation 10-Q Exhibit 10.1 U.S. Small Business Administration PPP Loan Document Input Requirements SBA Loan# 31931171-00 SBA Loan Name Nanophase Technologies Corporation Approval Date Apr 08, 2020 SBA Loan App # Date of Documents Apr 16, 2020 Loan Amount 951,600.00 Loan Payment Amount (to the penny) 53,290.05 Lender Name Libertyville Bank & Trust Company, N.A. Lender Addr

May 13, 2020 10-Q

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technolog

May 13, 2020 EX-10.2

Exhibit 10.2

Nanophase Technologies Corporation 10-Q Exhibit 10.2 LOAN AGREEMENT THIS LOAN AGREEMENT (“Agreement”) is made between Nanophase Technologies Corporation (“Borrower”), and Libertyville Bank & Trust Company, N.A. (“Lender”). The U.S. Small Business Administration (“SBA”) has authorized a guaranty (“Authorization”) of a loan from Lender to Borrower (“Loan”) having 2020 SBA Loan Number 31931171-00 whi

April 29, 2020 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 29, 2020 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commis

April 29, 2020 EX-99.1

Nanophase Reports First Quarter 2020 Financial Results Announces 8% Growth for Quarter, Outsized Formulated Product Sales

EXHIBIT 99.1 Nanophase Reports First Quarter 2020 Financial Results Announces 8% Growth for Quarter, Outsized Formulated Product Sales ROMEOVILLE, Ill., April 29, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmental aggressors, such as UV light and pollution, tod

April 21, 2020 EX-99.1

Nanophase Receives Funding Under Paycheck Protection Program

EXHIBIT 99.1 Nanophase Receives Funding Under Paycheck Protection Program ROMEOVILLE, Ill., April 21, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmental aggressors, such as UV light and pollution, today reported that it received funding in the form of a loan un

April 21, 2020 8-K

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

8-K 1 f8k042120.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 17, 2020 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdict

March 31, 2020 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 31, 2020 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission F

March 31, 2020 EX-99.1

Nanophase Reports 2019 Revenue Solésence Performs Well, First Half 2020 Outlook Positive

EXHIBIT 99.1 Nanophase Reports 2019 Revenue Solésence Performs Well, First Half 2020 Outlook Positive ROMEOVILLE, Ill., March 31, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmental aggressors, such as UV light and pollution, today reported financial results for

March 30, 2020 EX-21.1

SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2019)

Nanophase Technologies Corporation 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2019) Name Jurisdiction of Formation Solesence, LLC Delaware

March 30, 2020 10-K

Nanophase Technologies Corporation 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR

March 30, 2020 EX-10.42

FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT

Nanophase Technologies Corporation 10-K Exhibit 10.42 FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT This First Amendment is dated as of March 23, 2020 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of November 19, 2018 (“Lo

January 30, 2020 SC 13G/A

NANX / Nanophase Technologies Corp. / Conley John Howard Jr Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Nanophase Technologies Corp (Name of Issuer) Common Stock (Title of Class of Securities) 630079101 (CUSIP Number) (Date of Event which Requires Filing of this Statement) December 31, 2019 Check the appropriate box to designate the rule pursuant to which

January 14, 2020 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 (January 13, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (

December 4, 2019 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 nanx-8k120419.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2019 (December 3, 2019) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 3

November 22, 2019 EX-10.1

Exhibit 10.1*

NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 NANOPHASE TECHNOLOGIES CORPORATION 2019 EQUITY COMPENSATION PLAN The purpose of the 2019 Nanophase Technologies Corporation Equity Compensation Plan (the “Plan”) is to provide designated employees of Nanophase Technologies Corporation (the “Company”) and its subsidiaries, and certain advisors, including non-employee members of the Board of Direct

November 22, 2019 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2019 (November 19, 2019) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission

November 22, 2019 EX-3.1

Exhibit 3.1*

NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 3.1 FOURTH AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF NANOPHASE TECHNOLOGIES CORPORATION Pursuant to the Certificate of Incorporation of Nanophase Technologies Corporation, as amended, and the Delaware General Corporation Law, the undersigned corporation, organized and existing under and by virtue of the Delaware General Corporation Law, hereby

November 14, 2019 DEFA14A

NANX / Nanophase Technologies Corp. DEFA14A - - ADDITIONAL DEFINITIVE PROXY SOLITICING MATERIALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

November 14, 2019 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 14, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commissio

November 14, 2019 EX-99.1

Nanophase Reports Third Quarter 2019 Financial Results Announces 56% Growth for Year-Over-Year Formulated Product Sales The Company’s financial conference call is scheduled for November 15, 2019 at 4pm EST

EXHIBIT 99.1 Nanophase Reports Third Quarter 2019 Financial Results Announces 56% Growth for Year-Over-Year Formulated Product Sales The Company’s financial conference call is scheduled for November 15, 2019 at 4pm EST ROMEOVILLE, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for

November 14, 2019 EX-4.1

Exhibit 4.1

Nanophase Technologies Corporation 10-Q Exhibit 4.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (“Agreement”) dated as of November 13, 2019 by and between BRADFORD T. WHITMORE, an individual (“Whitmore” or “Purchaser”) and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (the “Company”). W I T N E S S E T H: WHEREAS, the Company, and its subsidiary, SOLÉSENCE, LLC, a Dela

November 14, 2019 EX-4.3

Exhibit 4.3

Nanophase Technologies Corporation 10-Q Exhibit 4.3 NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R

November 14, 2019 EX-4.2

Exhibit 4.2

Nanophase Technologies Corporation 10-Q Exhibit 4.2 COMMERCIAL SECURITY AGREEMENT THIS COMMERCIAL SECURITY AGREEMENT (“Agreement”) is dated as of November 20, 2019, and is made by NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“NTC”) and SOLÉSENCE, LLC, a Delaware limited liability company (“SLLC”), jointly and severally, in favor of BRADFORD T. WHITMORE (“Lender”). NTC and SLLC are r

November 14, 2019 10-Q

Nanophase Technologies Corporation 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Techn

October 17, 2019 DEF 14A

NANX / Nanophase Technologies Corp. DEF 14A - - DEFINITIVE PROXY STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

October 7, 2019 PRE 14A

NANX / Nanophase Technologies Corp. PRE 14A - - PRELIMINARY PROXY STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

August 28, 2019 EX-99.1

Nanophase Reports Second Quarter 2019 Financial Results Announces 150% Growth for Year-Over-Year Formulated Product Sales The company’s financial conference call is scheduled for August 29, 2019 at 11am EDT

EXHIBIT 99.1 Nanophase Reports Second Quarter 2019 Financial Results Announces 150% Growth for Year-Over-Year Formulated Product Sales The company’s financial conference call is scheduled for August 29, 2019 at 11am EDT ROMEOVILLE, Ill., Aug. 28, 2019 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products fo

August 28, 2019 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 28, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission

August 14, 2019 10-Q

Nanophase Technologies Corporation 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technologi

August 2, 2019 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2019 (July 31, 2019) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS E

August 2, 2019 EX-10.1

Exhibit 10.1

NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 CERTAIN INFORMATION, MARKED IN THIS EXHIBIT WITH BRACKETS, HAS BEEN EXCLUDED FROM THIS EXHIBIT IN RELIANCE ON REGULATION S-K, ITEM 601(B)(10)(IV) BECAUSE SUCH INFORMATION IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Joint Development Agreement This Joint Development Agreement (“Agreement”), da

May 15, 2019 EX-99.1

Nanophase Reports First Quarter 2019 Financial Results Announces 30% Growth for Quarter and Strong Formulated Product Sales The company’s financial conference call is scheduled for May 16, 2019 at 11am EDT

EXHIBIT 99.1 Nanophase Reports First Quarter 2019 Financial Results Announces 30% Growth for Quarter and Strong Formulated Product Sales The company’s financial conference call is scheduled for May 16, 2019 at 11am EDT ROMEOVILLE, Ill., May 15, 2019 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for

May 15, 2019 10-Q

Nanophase Technologies Corporation 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technolog

May 15, 2019 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 15, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission Fil

May 15, 2019 EX-4.1

Exhibit 4.1

Nanophase Technologies Corporation 10-Q Exhibit 4.1 NANOPHASE TECHNOLOGIES CORPORATION COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this “Agreement”) is made as of May 13, 2019 by and between Nanophase Technologies Corporation, a Delaware corporation with its principal office at 1319 Marquette Drive, Romeoville, Illinois 60446 (the “Company”), and Bradford T. Whitmore (the

May 15, 2019 EX-10.1

AMENDMENT NO. 4 TO ZINC OXIDE SUPPLY AGREEMENT

Nanophase Technologies Corporation 10-Q Exhibit 10.1 AMENDMENT NO. 4 TO ZINC OXIDE SUPPLY AGREEMENT THIS AMENDMENT NO. 4 TO ZINC OXIDE SUPPLY AGREEMENT is entered into as of January 1, 2019 by and between BASF CORPORATION, a Delaware corporation (“BASF”) and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Nanophase”). RECITALS A. Nanophase and BASF (as successor-in-interest to Sun Sma

April 24, 2019 8-K/A

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment to CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Em

April 11, 2019 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2019 (April 5, 2019) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS E

April 11, 2019 EX-10.1

Separation Agreement and General Release of All Claims, between Jaime Escobar and Nanophase Technologies Corporation, effective April 5, 2019

Nanophase Technologies Corporation 8-K Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS This Separation Agreement and General Release (“Agreement”) is made between Mr. Jaime Escobar and Nanophase Technologies Corporation (“NTC”). Whereas, since March 26, 2018, Mr. Escobar has served as Chief Financial Officer of NTC pursuant to that certain employment agreement between Mr. Escob

April 4, 2019 EX-21.1

SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2018)

NANOPHASE TECHNOLOGIES CORPORATION 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2018) Name Jurisdiction of Formation Solesence, LLC Delaware

April 4, 2019 EX-10.33

CHANGE IN TERMS AGREEMENT

NANOPHASE TECHNOLOGIES CORPORATION 10-K Exhibit 10.33 CHANGE IN TERMS AGREEMENT Borrower: Nanophase Technologies Corporation 1319 Marquette Drive Romeoville, IL 60446 Lender: Libertyville Bank and Trust Company 507 N. Milwaukee Ave Libertyville, IL 60048 (847) 367-6800 Principal Amount: $500,000.00 Date of Agreement: March 4, 2019 DESCRIPTION OF EXISTING INDEBTEDNESS. Promissory Note originally da

April 4, 2019 EX-10.32

BUSINESS LOAN AGREEMENT (ASSET BASED)

NANOPHASE TECHNOLOGIES CORPORATION 10-K Exhibit 10.32 BUSINESS LOAN AGREEMENT (ASSET BASED) Borrower: Nanophase Technologies Corporation Lender: Libertyville Bank and Trust Company 1319 Marquette Drive 507 N. Milwaukee Ave Romeoville, IL 60446 Libertyville, IL 60048 (847) 367-6800 THIS BUSINESS LOAN AGREEMENT (ASSET BASED) dated March 4, 2019, is made and executed between Nanophase Technologies Co

April 4, 2019 10-K

NANOPHASE TECHNOLOGIES CORPORATION 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR

March 29, 2019 NT 10-K

NANX / Nanophase Technologies Corp. NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-22333 CUSIP NUMBER: 630079101 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR For Period Ended: December 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form

March 27, 2019 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 27, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission F

March 27, 2019 EX-99.1

Nanophase Reports Record 2018 Revenue; Outlook for Solésence and Mineral UV Absorbers Strong The Company’s financial conference call is scheduled for March 28th at 11am EDT

EXHIBIT 99.1 Nanophase Reports Record 2018 Revenue; Outlook for Solésence and Mineral UV Absorbers Strong The Company’s financial conference call is scheduled for March 28th at 11am EDT ROMEOVILLE, Ill., March 27, 2019 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmen

March 15, 2019 EX-10.1

AMENDMENT NO.4 TO ZINC OXIDE SUPPLY AGREEMENT

Nanophase Technologies Corporation 8-K Exhibit 10.1 AMENDMENT NO.4 TO ZINC OXIDE SUPPLY AGREEMENT THIS AMENDMENT NO. 4 TO ZINC OXIDE SUPPLY AGREEMENT is entered into as of January 1, 2019 by and between BASF CORPORATION, a Delaware corporation (“BASF”) and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Nanophase”). RECITALS A. Nanophase and BASF (as successor-in-interest to Sun Smart

March 15, 2019 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) (Co

December 4, 2018 8-K

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2018 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) (

November 19, 2018 EX-10.2

PROMISSORY NOTE (Term Note)

Nanophase Technologies Corporation 10-Q Exhibit 10.2 PROMISSORY NOTE (Term Note) Principal Amount: $500,000.00 Date of Note: November 19, 2018 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (“Lender”), or order, in lawful money of the United States of America, the principal amou

November 19, 2018 10-Q

Nanophase Technologies Corporation 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Techn

November 19, 2018 EX-10.1

BUSINESS LOAN AGREEMENT

Nanophase Technologies Corporation 10-Q Exhibit 10.1 BUSINESS LOAN AGREEMENT THIS BUSINESS LOAN AGREEMENT dated as of November 19, 2018 by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), and BEACHCORP, LLC, a Delaware limited liability company (“Lender”). PREAMBLE WHEREAS, Borrower desires to enter into certain secured financial transactions with Lender for the

November 19, 2018 EX-10.3

PROMISSORY NOTE (Revolving Note)

Nanophase Technologies Corporation 10-Q Exhibit 10.3 PROMISSORY NOTE (Revolving Note) Principal Amount: $2,000,000.00 Date of Note: November 19, 2018 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (“Lender”), or order, in lawful money of the United States of America, the princip

November 15, 2018 NT 10-Q

NANX / Nanophase Technologies Corp. NOTICE UNDER RULE 12B25 OF INABIITY TO TIMELY FILE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-22333 CUSIP NUMBER: 630079101 (Check One): [ ] Form 10-K [ ] Form 20-F [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR For Period Ended: September 30, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Repo

November 1, 2018 EX-99.1

Nanophase Reports Third Quarter 2018 Financial Results

EXHIBIT 99.1 Nanophase Reports Third Quarter 2018 Financial Results Expects Record Year Driven by Solésence and Mineral UV Absorber Growth The Company’s financial conference call is scheduled for November 1, 2018 at 11am EDT ROMEOVILLE, Ill., Oct. 31, 2018 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated produc

November 1, 2018 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 31, 2018 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Comm

August 14, 2018 10-Q

Nanophase Technologies Corporation 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technologi

July 25, 2018 EX-99.1

Nanophase Reports Second Quarter 2018 Financial Results, Expects Another Record Year Driven by Solésence Growth The company’s financial conference call is scheduled for July 26, 2018 at 11am EDT

EXHIBIT 99.1 Nanophase Reports Second Quarter 2018 Financial Results, Expects Another Record Year Driven by Solésence Growth The company’s financial conference call is scheduled for July 26, 2018 at 11am EDT ROMEOVILLE, Ill., July 25, 2018 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB:NANX), a leader in personal care ingredients and products for protecting skin from environmental ag

July 25, 2018 8-K

NANX / Nanophase Technologies Corp. FORM 8-K (Current Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 25, 2018 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commiss

July 13, 2018 DEFA14A

NANX / Nanophase Technologies Corp. ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.

July 13, 2018 DEF 14A

NANX / Nanophase Technologies Corp. DEFINITIVE PROXY STATEMENT

DEF 14A 1 nanx-def14a082318.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a

May 31, 2018 SD

NANX / Nanophase Technologies Corp. SPECIALIZED DISCLOSURE REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1319 Marquette Drive, Romeoville, Illinois 60446 (Address of princ

May 25, 2018 EX-10.1

First Amendment to Supply Agreement, dated May 21, 2018, by and between Nanophase Technologies Corporation and Hallstar Ester Solutions Corporation (formerly known as Ester Solutions Company)

Nanophase Technologies Corporation 8-K Exhibit 10.1 FIRST AMENDMENT TO SUPPLY AGREEMENT This First Amendment to Supply Agreement (this “Amendment”) is made by and between Nanophase Technologies Corporation, a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 1319 Marquette Drive, Romeoville, IL 60446 (“Supplier”), and Hallstar Est

May 25, 2018 8-K

Nanophase Technologies Corporation 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2018 (May 21, 2018) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incor

May 24, 2018 EX-10.2

Amended and Restated Joint Development & Supply Agreement, executed by Solésence, LLC on May 18, 2018, by and between Solésence, LLC and Colorescience Inc.

NANOPHASE TECHNOLOGIES CORPORATION – 8-K EXHIBIT 10.2 Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for conf

May 24, 2018 EX-10.1

Joint Development & Supply Agreement, dated December 12, 2016, by and between Solésence, LLC and Colorescience Inc.

NANOPHASE TECHNOLOGIES CORPORATION – 8-K Exhibit 10.1 Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for conf

May 24, 2018 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2018 (May 18, 2018) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Empl

May 15, 2018 10-Q

Nanophase Technologies Corporation 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technolog

May 3, 2018 EX-99.1

Nanophase Reports First Quarter 2018 Financial Results The company’s financial conference call is scheduled for May 4, 2018 at 11am EDT

EXHIBIT 99.1 Nanophase Reports First Quarter 2018 Financial Results The company’s financial conference call is scheduled for May 4, 2018 at 11am EDT ROMEOVILLE, Ill., May 03, 2018 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB:NANX), a leader in specialty materials and skin protection technologies, today reported financial results for the first quarter ended March 31, 2018. “Followin

May 3, 2018 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 3, 2018 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commissio

March 30, 2018 EX-21.1

SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2017) Name Jurisdiction of Formation Solésence, LLC Delaware

EX-21.1 5 ex21-1.htm SUBSIDIARY OF THE COMPANY Nanophase Technologies Corporation 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2017) Name Jurisdiction of Formation Solésence, LLC Delaware

March 30, 2018 EX-10.33

Business Loan Agreement, executed by the Company on March 26, 2018, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.33 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Nanophase Technologies Corporation 10-K Exhibit 10.33 BUSINESS LOAN AGREEMENT (ASSET BASED) Borrower: Nanophase Technologies Corporation Lender: Libertyville Bank and Trust Company 1319 Marquette Drive 507 N. Milwaukee Ave Romeoville, IL 60446 Libertyville, IL 60048 (847) 367-6800 THIS BUSINESS LOAN AGREEMENT (ASSET BASED) dated March 4, 2018, is made and executed between Nanophase Technologies Co

March 30, 2018 10-K

Nanophase Technologies Corporation 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR

March 30, 2018 EX-10.34

Promissory Note, executed by the Company on March 26, 2018, granted by the Company in favor of Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.34 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Nanophase Technologies Corporation 10-K Exhibit 10.34 PROMISSORY NOTE Borrower: Nanophase Technologies Corporation Lender: Libertyville Bank and Trust Company 1319 Marquette Drive 507 N. Milwaukee Ave Romeoville, IL 60446 Libertyville, IL 60048 (847) 367-6800 Principal Amount: $500,000.00 Date of Note: March 4, 2018 PROMISE TO PAY. Nanophase Technologies Corporation (“Borrower”) promises to pay to

March 30, 2018 EX-10.35

Commercial Security Agreement, executed by the Company on March 26, 2018, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.35 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Nanophase Technologies Corporation 10-K Exhibit 10.35 COMMERCIAL SECURITY AGREEMENT Grantor: Nanophase Technologies Corporation Lender: Libertyville Bank and Trust Company 1319 Marquette Drive 507 N. Milwaukee Ave Romeoville, IL 60446 Libertyville, IL 60048 (847) 367-6800 THIS COMMERCIAL SECURITY AGREEMENT dated March 4, 2018, Is made and executed between Nanophase Technologies Corporation (“Grant

March 21, 2018 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 21, 2018 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commis

March 21, 2018 EX-99.1

Nanophase Reports Fourth Quarter and Fiscal Year 2017 Financial Results The company’s financial conference call is scheduled for March 22, 2018 at 11am EDT

EXHIBIT 99.1 Nanophase Reports Fourth Quarter and Fiscal Year 2017 Financial Results The company’s financial conference call is scheduled for March 22, 2018 at 11am EDT ROMEOVILLE, Ill., March 21, 2018 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB:NANX), a technology leader in nanomaterials and advanced nanoengineered products, today reported financial results for the fourth quarter

March 20, 2018 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2018 (March 16, 2018) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS

March 20, 2018 EX-99.1

Nanophase Announces New Chief Financial Officer

Nanophase Technologies Corporation 8-K Exhibit 99.1 COMPANY CONTACT Nancy Baldwin Investor Relations 630-771-6708 Nanophase Announces New Chief Financial Officer Romeoville, IL, - March 20, 2018 - Nanophase Technologies Corporation (OTCQB: NANX), a technology leader in nanomaterials and advanced nanoengineered products, announced today that the Company has hired Jaime Escobar to serve as its Chief

March 20, 2018 EX-10.1

Employment Agreement, executed by the Company on March 16, 2018 and effective as of March 26, 2018, by and between the Company and Jaime Escobar

Nanophase Technologies Corporation 8-K Exhibit 10.1 EMPLOYMENT AGREEMENT Employment Agreement dated and effective as of March 26, 2018 (this “Agreement”), between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (with its successors and assigns, referred to as the “Company”), and Jaime Escobar (referred to as Chief Financial Officer or CFO). Preliminary Statement The Company desires to e

December 29, 2017 SC 13G/A

NANX / Nanophase Technologies Corp. / Conley John Howard Jr Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Nanophase Technologies Corp (Name of Issuer) Common Stock (Title of Class of Securities) 630079101 (CUSIP Number) (Date of Event which Requires Filing of this Statement) December 31, 2017 Check the appropriate box to designate the rule pursuant to which

December 21, 2017 EX-4.1

Common Stock Purchase Agreement, dated December 19, 2017, between Nanophase Technologies Corporation and Bradford T. Whitmore

Nanophase Technologies Corporation 8-K Exhibit 4.1 NANOPHASE TECHNOLOGIES CORPORATION COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this ?Agreement?) is made as of December 19, 2017 by and between Nanophase Technologies Corporation, a Delaware corporation with its principal office at 1319 Marquette Drive, Romeoville, Illinois 60446 (the ?Company?), and Bradford T. Whitmore

December 21, 2017 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 19, 2017 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) (

November 14, 2017 10-Q

Nanophase Technologies Corporation 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Techn

October 25, 2017 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 25, 2017 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Comm

Other Listings
US:SLSN US$ 3.26
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista